Detalhe da pesquisa
1.
Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.
Ther Drug Monit
; 46(3): 291-308, 2024 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38648666
2.
Tocilizumab Dose Tapering Based on a Model-Based Algorithm is Feasible in Clinical Practice: A Short Communication.
Ther Drug Monit
; 46(3): 410-414, 2024 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38287880
3.
EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases.
Ann Rheum Dis
; 82(1): 65-73, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35551063
4.
Single dose tocilizumab for COVID-19 associated cytokine storm syndrome: Less is more.
Br J Clin Pharmacol
; 2023 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36791777
5.
Adalimumab combined with methotrexate versus adalimumab monotherapy in psoriasis: Three-year follow-up data of a single-blind randomized controlled trial.
J Eur Acad Dermatol Venereol
; 37(9): 1815-1824, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37014287
6.
Drug levels, anti-drug antibodies and B-cell counts were not predictive of response in rheumatoid arthritis patients on (ultra-)low-dose rituximab.
Rheumatology (Oxford)
; 61(10): 3974-3980, 2022 10 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35022672
7.
Anti-rituximab antibodies affect pharmacokinetics and pharmacodynamics of rituximab in children with immune-mediated diseases.
Clin Exp Rheumatol
; 40(1): 183-190, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34251329
8.
Comprehensive evaluation of microneedle-based intradermal adalimumab delivery vs. subcutaneous administration: results of a randomized controlled clinical trial.
Br J Clin Pharmacol
; 87(8): 3162-3176, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33403697
9.
Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial.
Scand J Gastroenterol
; 56(2): 145-154, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33290108
10.
Infliximab Level Between Venous and Capillary Blood Using Novel Device Strongly Correlate in Paediatric Inflammatory Bowel Disease Patients.
J Pediatr Gastroenterol Nutr
; 72(1): 56-60, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32804907
11.
Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease.
Gastroenterology
; 157(4): 997-1006.e6, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31175865
12.
Monitoring of Adalimumab Concentrations at Home in Patients with Inflammatory Bowel Disease Using Dried Blood Samples.
Ther Drug Monit
; 42(2): 289-294, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31464823
13.
The effect of certolizumab drug concentration and anti-drug antibodies on TNF neutralisation.
Clin Exp Rheumatol
; 38(2): 306-313, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31498069
14.
Vedolizumab Trough Levels in Children With Anti-Tumor Necrosis Factor Refractory Inflammatory Bowel Disease.
J Pediatr Gastroenterol Nutr
; 71(4): 501-507, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32639455
15.
HLA-DRB1 and HLA-DQA1 associated with immunogenicity to adalimumab therapy in patients with rheumatoid arthritis.
Ann Rheum Dis
; 83(2): 263-265, 2024 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37699653
16.
Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation.
Br J Clin Pharmacol
; 85(7): 1544-1551, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30927375
17.
Comparison of Immunoassays for Measuring Serum Levels of Golimumab and Antibodies Against Golimumab in Ulcerative Colitis: A Retrospective Observational Study.
Ther Drug Monit
; 41(4): 459-466, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30817702
18.
Antidrug antibody detection for adalimumab depends on the type of assay used: an experimental approach to help clinicians interpret diagnostic data.
Clin Exp Rheumatol
; 37(5): 756-761, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30943139
19.
The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing.
Mult Scler
; 24(6): 805-810, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28485678
20.
From natalizumab to fingolimod in eight weeks - Immunological, clinical, and radiological data in quest of the optimal switch.
Clin Immunol
; 176: 87-93, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28108364